NovaBridge Biosciences (NBP) Non-Current Deffered Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has reported Non-Current Deffered Revenue for 6 consecutive years, with $40.6 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Non-Current Deffered Revenue rose 7.72% year-over-year to $40.6 million; the TTM figure through Dec 2023 stood at $40.6 million (up 7.72% YoY), while the FY2023 annual figure was $41.2 million, up 1618.54% from the prior year.
• Non-Current Deffered Revenue improved to $40.6 million in Q4 2023 per NBP's latest filing, from $36.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $35.0 billion in Q4 2021 and bottomed at $556172.6 in Q4 2019.
• Historically, Non-Current Deffered Revenue has averaged $5.0 billion across 5 years, with a median of $36.9 million in 2023.
• Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue jumped 53.82% — and 2022, when it sank 99.89%.
• NovaBridge Biosciences' Non-Current Deffered Revenue stood at $556172.6 in 2019, then climbed by 20.83% to $672000.0 in 2020, then surged by 5213553.04% to $35.0 billion in 2021, then tumbled by 99.89% to $37.7 million in 2022, then rose by 7.72% to $40.6 million in 2023.
• Business Quant data shows NBP's Non-Current Deffered Revenue at $40.6 million in Q4 2023, $36.9 million in Q2 2023, and $37.7 million in Q4 2022.